Collaborative Practice Agreement · PharmD
Maine CDTM Agreement for Pharmacists
Required. The CDTM Agreement is the written instrument Maine law names for a Pharmacist working with a physician. Below: the board that governs it, what it must contain, and the terms it has to carry.
Represents Maine's optional pharmacist-practitioner Collaborative Drug Therapy Management (CDTM) agreement tier under 32 M.R.S. § 13843, not ordinary pharmacist licensure — base dispensing needs no agreement. The collaborating practitioner supervises or provides direct consultation throughout; the pharmacist's lab-result evaluation may not include a diagnostic component.
What a Maine CDTM Agreement must contain
Governed by the Maine Board of Pharmacy. Each numbered item is a statutory requirement the agreement must satisfy.
The Pharmacist may practice collaborative drug therapy management ("CDTM") with the Physician pursuant to a written, signed agreement satisfying 32 M.R.S. § 13843. The agreement shall identify the Parties and its effective dates, include a termination clause allowing either Party to cancel by written notice, state the practice site, describe the Pharmacist's qualifications, describe in detail the diseases, drugs, or drug categories covered, establish a procedure for referring patients back to the Physician, establish a procedure for reviewing and revising the agreement, establish a plan for measuring patient outcomes, and confirm the Pharmacist's liability insurance and compliance with HIPAA.
Source: 32 M.R.S. § 13843
For the first three (3) months under the agreement, the Pharmacist is limited to monitoring drug therapy. After that period, the Parties may amend the agreement to authorize the Pharmacist to initiate, administer, monitor, modify, and discontinue drug therapy within the diseases, drugs, and drug categories the agreement describes; the Pharmacist has no authority under this Agreement to initiate, modify, or discontinue drug therapy outside the specific terms of the then-current written CDTM agreement. A copy of the agreement shall be submitted to the Maine Board of Pharmacy and to the Physician's licensing board before the collaborative practice commences, and any amendment shall be resubmitted before it takes effect.
Source: 32 M.R.S. § 13843
- The CDTM Agreement on file also carries 1 scope, 1 education, 1 registration, 1 authority clauses, generated in the document itself.
Statutes and rules cited
- 32 M.R.S. § 2102(2-A)statute
24-month post-certification supervision/collaboration requirement for certified nurse practitioners, pending Board of Nursing rulemaking under § 2205-B(4-A).
- 32 M.R.S. § 2205-B(4-A)statute
Directs the Maine State Board of Nursing to adopt new APRN practice standards to replace the flat 24-month supervision rule; rules may not be adopted before May 1, 2026.
- 32 M.R.S. § 3270-Gstatute
Physician associate scope-of-practice and Collaborative Agreement / Practice Agreement requirements under the Board of Licensure in Medicine.
- 32 M.R.S. § 2594-Fstatute
Mirror-image physician assistant scope-of-practice and agreement requirements under the Board of Osteopathic Licensure.
- 32 M.R.S. § 13842statute
Pharmacist qualifications to enter a collaborative drug therapy management agreement.
- 32 M.R.S. § 13843statute
Mandatory content of a collaborative drug therapy management agreement, the initial 3-month monitoring-only period, and the requirement to submit the agreement to the Board of Pharmacy and the prescriber's licensing board before commencement.
Terms it has to carry
Ratio, proximity, chart review, meeting and prescribing terms the agreement has to carry, from the state's supervision rules.
Proximity
Not codified — left to the agreement
Supervision ratio
Not codified — no cap on file
Chart review
Not codified — left to the agreement
Meeting cadence
Not codified — left to the agreement
Prescriptive authority
Covered by the practice agreement · no controlled-substance authority
Under a CDTM agreement, the pharmacist initiates, administers, monitors, modifies, and discontinues drug therapy as authorized by the practitioner (32 M.R.S. § 13702-A) — delegated drug-therapy management, not independent DEA-registered controlled-substance prescribing, so controlledSubstancesAllowed is coded False here. Whether CDTM terms may extend to controlled substances was not confirmed in this pass.
Written agreement
Required
Only required if the pharmacist and a practitioner elect to engage in collaborative drug therapy management — a pharmacist's base license and general dispensing authority need no such agreement (32 M.R.S. §§ 13842-13843).
Practice ownership (corporate practice of medicine)
Non-licensee ownership permitted — No pharmacist-ownership requirement was identified for Maine pharmacy permits in this pass — not independently confirmed against a specific statute/reg; treat as consistent with the typical non-restrictive pharmacy-ownership pattern seen in other states rather than a settled Maine-specific finding.
Materially more permissive than the physician/APRN professional-entity questions above, if confirmed.
Legal sources for these rules (4)
About Maine's rules
Maine's provider categories follow different independence models: NPs graduate to full practice after 24 months of registered (not written-agreement) supervision; PAs graduate after 4,000 documented clinical hours but still need a lighter 'practice agreement' afterward; CNMs/CNSs appear independent from initial licensure; and CRNAs remain physician/dentist-accountable except in critical-access/rural hospitals. Do not assume a single APRN framework applies uniformly.
Other clinicians in Maine: see the state overview.